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found significant metabolomic changes at 2 h PT, whereas 
the integrity of neurons and glia, at the anatomical/ neuro-
chemical level, was not significantly altered during the first 
5 h PT for the majority of histological markers.
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Brain tissue obtained from autopsy is practically the only 
source of normal brain tissue that can be used to study the 
structure of the human brain. In general, the major limita-
tion is the post-mortem time (PT) since the longer the PT 
delay, the larger are the alterations observed in the meas-
urements at all levels of biological organization (genetic, 
molecular, biochemical, anatomical). Previous studies 
with a large variety of techniques have shown alterations 
in expression levels of structural proteins and enzymes 
and in the integrity of nucleic acids, as well as changes in 
the morphology of neurons, receptors for neurotransmit-
ters or their transporters at several PTs (Buell 1982; Hil-
big et  al. 2004; Williams et  al. 1978; Perry et  al. 1981; 
Spokes 1979). In addition, brain fixation and storage time 
as well as certain antemortem factors (age, sex, use of toxic 
Abstract Understanding the human brain is the ulti-
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ing in part due to the fact that brain tissue obtained from 
autopsy is practically the only source of normal brain tis-
sue and also since changes at different levels of biological 
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we used metabolomic and anatomical techniques to study 
the possible relationship between post-mortem time (PT)-
induced changes that may occur at both the metabolomics 
and anatomical levels in the same brains. Our experiments 
have mainly focused on the hippocampus of the mouse. We 
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substances and drugs, duration of agonal state, etc.) are all 
critical and should be considered as they may affect meas-
urements. Thus, brain banks take special care in trying to 
provide high-quality human tissue for research by perform-
ing rapid autopsies and collecting tissue, including match-
ing for several factors both antemortem and post-mortem 
(Ravid and Swaab 1993).
Perfused animal brains are the source of tissue in most 
experimental laboratories. For obvious reasons, in humans, 
we cannot directly test the differences that may occur 
between tissue fixed by perfusion with no PT delay and tis-
sue obtained after autopsy. In previous studies, it has been 
shown that the biopsy material obtained during neurosur-
gical treatment for epilepsy or for removing certain brain 
tumors represents an excellent opportunity to study the 
microanatomy of the human brain because the resected tis-
sue can be immediately immersed in the fixative (Del Rio 
and DeFelipe 1994; Alonso-Nanclares et  al. 2008). Thus, 
this tissue is lacking possible post-mortem time-induced 
changes that may occur at both the neurochemical and 
anatomical levels, which is the major problem when using 
brain tissue from autopsies. Therefore, this kind of tissue is 
of great value since, for clear ethical reasons, it is as close 
to a “normal” sample of brain tissue as is possible to obtain 
for studying the human brain. The major limitation is that 
different medical characteristics of the patients (i.e., differ-
ences in the medication, severity of the disease, onset and 
duration) may modify the brain tissue. Furthermore, the 
major source of biopsy material is from the anterior part 
of the temporal lobe and, therefore, studies in other regions 
of the brain are scarce. For these reasons, it is important to 
define what a good quality of human brain tissue obtained 
at autopsy is when studying any region of the human brain. 
In general, at least 1- to 2-h PT delay is the minimum time 
that can be achieved and indeed this is the exception; in 
most brain banks, PT is 5–10 or more hours before fixa-
tion. This is an important limitation, but, unfortunately, ani-
mal experimental data are often extrapolated to the human 
brain without considering the PT delay factors. For exam-
ple, it is common to describe similar or different patterns of 
immunostaining when comparing brain tissue from humans 
with experimental animals without considering these meth-
odological factors. Nevertheless, some measurements are 
rather stable for many hours, whereas others may rapidly 
change in minutes after death. Therefore, it is of great rel-
evance to know which are the most sensitive and reliable 
markers of tissue quality to analyze aspects of the healthy 
and diseased brain structure at different levels of biological 
organization in post-mortem cases.
As described in the literature, the rapidly emerging field 
of metabolomics has been proven to provide very use-
ful information regarding the biochemical basis of neuro-
logical and psychiatric disorders, using different analytical 
platforms and statistical and multi-variant methods for 
information extraction and data interpretation (Durren-
berger et al. 2010). However, very little is known about the 
possible relationship between PT-induced changes that may 
occur at both the metabolomics and anatomical levels in 
the same brains. In the present study, we have attempted to 
analyze these changes in the same brains with different PT 
intervals. We have mainly focused on the hippocampus, as 
this brain region is the target of numerous studies of major 
brain diseases such as Alzheimer’s disease and epilepsy. 
We selected different PT intervals of up to 5  h since, in 
our experience, after this period fine anatomical tools like 
intracellular injections in fixed material or electron micros-
copy techniques do not render satisfactory results, whereas 
the results are excellent with shorter times (Merino-Serrais 
et  al. 2013; Blazquez-Llorca et  al. 2013, 2010). Here we 
used mass spectrometry coupled to several separation tech-
niques (GC–MS and LC–MS) and a variety of histological, 
histochemical and immunohistochemical techniques that 
are commonly used to study the neuroanatomical character-
istics of the brain in both health and disease. Furthermore, 
to find an explanation for the degree of metabolite retention 
existing at a precise time after death, we tried to interpret 
the obtained results from a biological point of view, provid-
ing insight into the hypoxic and decomposition post-mor-
tem reactions. The examination of the trend of the amino 
compounds, lipids and related metabolites in hippocampus 
tissue made it possible to assess some of the changes that 
occur over time following death (Perry et al. 1981). Finally, 
we compared the neuroanatomical and neurochemical char-
acteristics of brain tissue obtained after perfusion with 
immersion-fixed brain tissue that was extracted immedi-




This study was performed in 2-month-old male C57BL/6 J 
mice (Charles River Laboratories, Wilmington, MA). Mice 
were kept in a 12:12-h light/dark cycle and received food 
and water ad libitum. All experimental protocols involv-
ing the use of animals were performed in accordance with 
recommendations for the proper care and use of laboratory 
animals and under the authorization of the regulations and 
policies governing the care and use of laboratory animals 
[EU directive no. 86/609 and Council of Europe Conven-
tion ETS1 23, EU decree 2001-486 and Statement of Com-
pliance with Standards for Use of Laboratory Animals by 
Foreign Institutions no A5388-01, National Institutes of 
Health (USA)]. Special care was taken to minimize animal 
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suffering and to reduce the number of animals used to the 
minimum required for statistical accuracy.
In this study, we used two groups of mice, one prepared 
for histology and immunohistochemistry and the other for 
metabolomic assays as follows.
Anatomy: tissue processing, histology 
and immunohistochemistry
One group was anaesthetized with a pentobarbital lethal 
injection (40  mg/kg BW, Vetoquinol, Madrid, Spain) and 
transcardially perfused with 20 mL of 0.1 mol/L phosphate 
buffer (PB), followed by 150 mL of 4% paraformaldehyde 
in PB. The brains were removed from the skull, post-fixed 
in the same solution for 20  h and cryoprotected in 30% 
sucrose for 2 days. Finally, the brains were flash-frozen in 
isopentane (2-methylbutane, Merck, Billerica, MA), cooled 
in a 70% ethanol-dry ice bath and stored at −80  °C until 
cutting.
The second group of mice was killed with the same 
pentobarbital lethal injection as described above. Thereaf-
ter, their brains were removed after the following PT inter-
vals: 0′ h (0′ min), 30 min, 1, 2, 3 and 5 h (n = 3 animals per 
interval) as follows: Their bodies were maintained at room 
temperature (animals with PT delay of 30 min, 1 h, 2 h and 
3 h), or 2 h at room temperature followed by 3 h at 4 °C in 
a fridge (animals with PT of 5 h). The skull was maintained 
joined to the body until decapitation, after which the brains 
were removed from the skull and fixed in PB-buffered 4% 
paraformaldehyde for 20 h overnight at 4 °C. After fixation, 
brains were cryoprotected and frozen as described previ-
ously for the perfused tissue.
The brain tissue from the two groups of animals was 
cut into 30-μm-thick coronal slices with a freezing sliding 
microtome (Microm HM 450, Microm International, Ger-
many) and processed for histological, histochemical and 
immunohistochemical experiments (immunoperoxidase 
and immunofluorescence). For a comprehensive list of the 
antibodies used and their characteristics, see Supplemen-
tary Table S1.
Histochemical experiments involved staining for nico-
tine adenine dinucleotide phosphate (NADPH)-diapho-
rase (NADPH-d) according to the protocol of Hope and 
Vincent (1989). Briefly, sections were washed in 50  mM 
Tris–HCl, pH 7.4 and incubated for 60  min at 37  °C in 
1 mM β-NADPH (Sigma, St Louis, MO), 0.5 mM nitroblue 
tetrazolium (NBT; Sigma) and 0.1% Triton X-100 in 
50  mM Tris–HCl, pH 8. The sections were then rinsed 
in 50 mM Tris–HCl, pH 7.4 and washed in PB. The sec-
tions were mounted, dehydrated, cleared in xylene and then 
coverslipped.
Immunoperoxidase stainings were carried out in free-
floating sections under moderate shaking. The endogenous 
peroxidase activity was quenched for 1  h at room tem-
perature in a solution of 2% hydrogen peroxide in 100% 
methanol. After several washes in 0.1 M phosphate buffer 
(pH 7.4), containing 0.3% TritonX-100 (washing buffer), 
sections were incubated overnight at 4 °C with one of the 
following primary antibodies: anti-NeuN (ABN78, rabbit 
polyclonal, Millipore, Billerica, MA; diluted 1:2000); anti-
calbindin D28K (rabbit polyclonal, Swant, Switzerland; 
diluted 1:2000); anti-parvalbumin (PV-25, rabbit poly-
clonal, Swant, Switzerland; diluted 1:2000); anti-SMI-32 
(SMI-32R, mouse monoclonal, Covance, Princeton, NY; 
diluted 1:4000); anti-type 1 vesicular glutamate trans-
porter (vGLUT1) (AB5905, guinea pig polyclonal, Mil-
lipore, Billerica, MA; diluted 1:5000); anti-type 2 vesicu-
lar glutamate transporter (vGLUT2) (AB2251, guinea 
pig polyclonal, Millipore, Billerica, MA; diluted 1:2000); 
anti-vesicular gamma-aminobutyric acid transporter vGAT 
(131003, rabbit polyclonal, Synaptic systems, Göttingen, 
Germany; diluted 1:2000); anti-Iba1 (ionized calcium bind-
ing adaptor protein 1) (019-19741, Wako, Osaka, Japan; 
diluted 1:500); anti-GFAP (Glial Fibrillary Acidic Protein) 
(G9269, rabbit polyclonal, Sigma-Aldrich, St Louis. MO; 
diluted 1:500); and anti-glutamate decarboxylase (GAD) 
65 (AB5082, rabbit polyclonal, Millipore, Billerica, MA; 
diluted 1:1000 and ab203063, rabbit polyclonal, Abcam, 
Cambridgde, UK; diluted 1:500).Primary antibodies were 
diluted in washing buffer containing 3% normal goat serum 
or normal horse serum. After incubation with the primary 
antibody, sections were then rinsed in buffer and incubated 
for 2  h at room temperature with biotinylated horse anti-
mouse immunoglobulin G (BA2000, Vector laboratories, 
Burlingame, CA; diluted 1:250 in washing buffer), bioti-
nylated goat anti-guinea pig immunoglobulin G (BA7000, 
Vector laboratories, Burlingame, CA; diluted 1:250 in 
washing buffer) or biotinylated goat anti-rabbit immuno-
globulin G (BA1000, Vector laboratories, Burlingame, CA; 
diluted 1:250 in washing buffer). After several washes in 
buffer, sections were incubated for 1  h at room tempera-
ture with avidin–biotin peroxidase complex (ImmunoPure 
ABC, Pierce, Rockford, IL; diluted 1:125). Peroxidase 
activity was revealed with 0.01% hydrogen peroxide, using 
3,3ʹ-diaminobenzidine (Sigma, St Louis. MO; 0.05%). 
Finally, sections were mounted, dehydrated and coun-
terstained with methyl green (Sigma, St. Louis, MO) and 
coverslipped with DEPEX (VWR, Rannor, Pennsylvania). 
The slides were observed with a digital microscope (Zeiss). 
Immunostaining was absent when the primary antibody 
was omitted. All the experimental groups were assayed in 
parallel.
For immunofluorescence, free-floating sections were 
incubated overnight at 4 °C with one of the following 
primary antibodies at the dilutions described above: anti-
NeuN; anti-parvalbumin; anti-vGLUT1; anti-vGLUT2; 
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and anti-vGAT, in washing buffer containing 3% normal 
goat serum. Sections were then rinsed in buffer and incu-
bated for 2 h at room temperature with 3% normal goat 
serum and the following secondary antibodies: Alexa 
Fluor 594-conjugated goat anti-mouse (A11005, Molecu-
lar Probes, Madrid, Spain), Alexa Fluor 594-conjugated 
goat anti-rabbit (A11012, Molecular Probes, Madrid, 
Spain) and Alexa Fluor-647-conjugated goat anti-guinea 
pig (A21450, Molecular Probes, Madrid, Spain). The 
nuclei were counterstained with DAPI (4′,6-diamidino-
2-phenylindole) (Sigma, San Louis; MO; diluted 1:80). 
Sections were mounted on histological slides and cover-
slipped with  ProLong® Gold antifade reagent (Life tech-
nologies, Carlsbad, CA).
Possible alterations in the structure and distribution 
of the extracellular matrix constituents of perineuronal 
nets, which surround PV-positive GABAergic interneu-
rons, were assessed by double fluorescence staining using 
fluorescein-Wisteria floribunda lectin (WFL) (Vector 
Laboratories, 1:500) that recognizes N-acetylgalactosa-
mine residues in the extracellular matrix. This staining 
was used in combination with immunocytochemistry 
using anti-GAD-65 antibodies or anti-SMI-32 antibodies. 
GAD-65 antibodies label subpopulations of inhibitory 
neurons, whereas anti-SMI-32 antibodies label a subset 
of excitatory (a subpopulation of pyramidal neurons) and 
inhibitory neurons (a subpopulation of interneurons). The 
sections were incubated overnight at 4  °C with primary 
antibodies and WFL at the dilutions described previously 
and were then incubated with the following secondary 
antibodies: Alexa Fluor 594-conjugated goat anti-mouse 
(A11005, Molecular Probes, Madrid, Spain) or Alexa 
Fluor 594-conjugated goat anti-rabbit (A11012, Molecu-
lar Probes, Madrid, Spain). The sections were stained 
with DAPI, after rinsing in PB, and were then treated 
with Autofluorescence Eliminator Reagent (Chemicon) to 
reduce autofluorescence according to the manufacturer’s 
instructions, mounted in antifade mounting medium (Pro-
longGold, Invitrogen) and studied by confocal micros-
copy (Zeiss, 710).
Fluorescence images were acquired using a LSM710 
confocal laser-scanning microscope (Carl Zeiss MicroIm-
aging, Jena, Germany). Z sections were recorded at 1-μm 
intervals through separate channels, and subsequently, ZEN 
2012 software (Zeiss) was used to construct composite 
images from each optical series by combining the images 
recorded through the different channels. Finally, sections 
adjacent to those used for histochemistry and immuno-
histochemistry were stained with thionine or cresyl violet 
to reveal the borders between the different layers and hip-
pocampal fields and to examine possible changes in the 
general cytoarchitectural characteristics under the different 
experimental conditions.
Metabolomics: tissue processing and reagents, sample 
treatments, analysis methods, data processing, 
statistical analysis and compound identification
For metabolomics studies, we followed the same protocol 
for the removal of the brains as that described above for the 
analysis of immersion-fixed tissue. However, after removal 
of the brains (n = 15), they were kept on ice, while the left 
hippocampi were dissected. The samples were then frozen 
on liquid nitrogen and stored at −80  °C until processed. 
Tissue samples were divided into three groups (n = 5 per 
group) according to the PT that had elapsed when brains 
were extracted from the animals: 30 min, 2 h and 5 h.
Reverse-osmosed ultrapure water, used to prepare all the 
aqueous solutions, was obtained “in-house” from a Milli-
Qplus185 system (Millipore, Billerica, MA, USA). LC–MS 
grade methanol and analytical grade formic acid were 
from Sigma-Aldrich (Steinheim, Germany). Analytical 
grade ammonia hydroxide (30% ammonium in high purity 
water) was acquired from Panreac Quimica SA (Barce-
lona, Spain). Reagents for derivatization (O-methoxyamine 
hydrochloride and BSTFA:TMCS, 99:1 (Sylon BFT)) were 
purchased from Sigma-Aldrich (Steinheim, Germany) and 
Supelco (Bellefonte, PA, USA), respectively. Standard 
mix for GC–MS, containing grain fatty acid methyl esters 
(C8:0-C22:1, n9), and analytical grade heptane were pur-
chased from Fluka Analytical (Sigma-AldrichChemie 
GmbH, Steinheim, Germany). Silylation-grade pyridine 
was from VWR International BHD Prolabo (Madrid, 
Spain). Methyl-tert-butyl-ether (MTBE) used for hydro-
phobic compounds extraction was acquired from Sigma-
Aldrich (Steinheim, Germany).
Sample treatment procedure for metabolite extractions
Brain samples were prepared for LC–MS and GC–MS at 
CEMBIO (Madrid, Spain). The method used for the extrac-
tion was previously developed and validated at CEMBIO 
for lung tissue (Naz et al. 2013) and was selected, after test-
ing, from several different extraction conditions because it 
also provided a higher number of reproducible signals for 
brain. Briefly, approximately 30 mg of hippocampus tissue 
was used for the study, and samples were stored at −80 °C 
until the analysis. The solvent used for the tissue homog-
enization was MetOH:  H2O 50% (v/v), (1:10 tissue/sol-
vent). Samples were homogenized using a TissueLyser LT 
homogenizer (Qiagen, Germany). For extraction, 100 μL 
of hippocampus tissue homogenate was vortex-mixed with 
320 μL of methanol for 2 min after which 80 μL of MTBE 
was added. Vials were immediately capped and placed on a 
shaker for 1 h at room temperature. The extracted samples 
were then centrifuged at 4000g at 20  °C for 20  min, and 
90 μL of supernatant was transferred to a chromatography 
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vial for LC–MS analysis and 300 μL to a separate vial for 
GC–MS analysis. For LC–MS analysis, the supernatant 
was injected directly into the system.
For GC–MS, 300 μL of supernatant was evaporated to 
dryness using a SpeedVac Concentrator System. Methoxy-
mation was performed with O-methoxyamine hydrochlo-
ride (15 mg/mL in pyridine) and vigorously vortex-mixed 
for 5  min. For silylation, 20 μL of BSTFA:TMCS (99:1) 
was added, vortex-mixed for 5 min, and capped vials were 
placed in the oven at 70 °C for 1 h. Prior to injection, 100 
μL of heptane containing C18:0 methyl ester (10 ppm) as 
IS was added.
Quality control samples (QC) were prepared by pooling 
equal volumes (approx. 100 μL) of hippocampus homoge-
nate from each of the 15 samples. Five QC samples were 
independently prepared in parallel by dividing up the total 
volume of this pooled QC. These QCs were treated as the 
rest of the samples and were analyzed throughout the run to 
provide a measurement not only of the stability and perfor-
mance of the system, but also of the reproducibility of the 
sample treatment procedure.
Hippocampus fingerprinting by LC-QTOF-MS
Metabolic fingerprinting performed in LC-QTOF-MS 
was carried out with a liquid chromatography (LC) sys-
tem (1200 series, Agilent Technologies, Waldbronn, Ger-
many) consisting of a degasser, two binary pumps, ther-
mostated autosampler, maintained at 15  °C and a column 
oven. Based on previously optimized conditions for lipid-
omic analysis (Whiley et al. 2012), 10 μL of extracted hip-
pocampus samples was injected into a reverse phase col-
umn (Agilent; Poroshell EC-C8, 15 cm × 2.1 mm, 2.7 μm) 
with a guard column (Supelco Ascentis Express C8, 
0.5 cm × 2.1 mm, 2.7 μm) thermostated at 60 °C. The gra-
dient used for the analysis consisted of a mobile phase A 
(5  mM ammonium formate in Milli-Q water) and mobile 
phase B (5  mM ammonium formate in methanol/isopro-
panol, 85:15) pumped at 0.5 mL/min. Initial conditions 
at time 0 were 82% B, increasing to 96% B in 30  min. 
This was then maintained until 38 min. The gradient then 
increased to 100% B by 38.5 min and was maintained for 
2 min until 40.5 min. The starting condition was returned 
to by 42 min, followed by an 8-min re-equilibration time, 
taking the total run time to 50  min. Data were collected 
in positive ESI mode on a QTOF (6520 Agilent Tech-
nologies) with a scan rate of 1.02 scans/s operated in full 
scan mode from 100 to 1200  m/z. The capillary voltage 
was 3500  V, the nebulizer gas flow rate was 10.0  L/min, 
the source temperature was 350 °C, and its pressure was 40 
psi. Two reference masses were used in the course of the 
whole analysis: m/z 121.0509 (protonated purine,  C5H4N4) 
and m/z 922.0098 (HP-921,  C18H18O6N3P3F24) for positive 
ionization mode. Masses were continuously infused into 
the system to provide constant mass correction. Samples 
were analyzed randomly in the run.
Hippocampus fingerprinting by GC-Q-MS
The analysis of the derivatized extracts was performed with 
an Agilent GC instrument (7890  A) coupled to an inert 
mass spectrometer with Triple-Axis Detector (5975  C, 
Agilent Technologies). The injection volume of derivat-
ized samples was set at 2 μL using an Agilent autosampler 
(7693). Samples were automatically injected in split mode, 
with a split ratio 1:10, into an Agilent deactivated glass 
wool split liner. Separation of the compounds was achieved 
using a 10 m J&W precolumn (Agilent Technologies) inte-
grated with a 122 − 5332G column: DB5-MS 30 m length, 
0.25  mm i.d. and 0.25  μm film consisting of 95% dime-
thyl/5% diphenyl polysiloxane (Agilent Technologies). 
The Helium carrier gas flow was held constant at 1 mL/
min. The lock of the retention time (RTL) relative to the 
internal standard (methyl stearate C18) peak at 19.66 min 
was performed. The initial column oven temperature was 
set at 60 °C (maintained for 1 min), then raised by 10 °C/
min until it reached 325 °C and was held at this tempera-
ture for 10  min before cooling down. The injector and 
the transfer line temperatures were set at 250 and 280 °C, 
respectively. MS system: The electron impact ionization 
operating parameters were set as follows: filament source 
temperature, 230  °C; electron ionization energy, 70  eV. 
Mass spectra were collected from 50 to 600 m/z at a scan 
rate of 2 spectra/s. Data were acquired using the Agilent 
MSD ChemStation software (Agilent Technologies).
Data processing
For a global profiling, raw data collected by GC–MS 
and LC–MS were reprocessed using different software 
packages.
GC–MS data treatment Total ion chromatograms (TICs) 
were inspected based on the quality of the chromatograms 
and internal standard signal. First, samples were processed 
with MassHunter Workstation GC/MS Translator software 
version B.04.01, in order to reformat data files as necessary 
to conform to the MassHunter Quantitative data analysis 
format. Deconvolution and metabolite identification of raw 
data collected by GC/MS analysis were performed by Agi-
lent MassHunter Unknowns Analysis Tool 7.0. A chemical 
identity was assigned to the compounds by the software 
by searching in two target libraries: Fiehn library version 
2008 and the CEMBIO in-house spectral library by compar-
ing both retention time (RT) and spectra extracted during 
the deconvolution against each compound included in the 
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library (Kind et al. 2009). In addition, a commercial spectral 
library—NIST (National Institute of Standards and Tech-
nology) library 2.2 version 2014—was used for compar-
ing non-identified compounds. Those with spectrum score 
>80% and concordant retention index (n-alkane scale) were 
putatively identified according to NIST. Data obtained by 
the Unknown Analysis Tool were aligned using MassPro-
filer Professional B.12.1 (Agilent Technologies). Assign-
ment of the target ions and signal integration was performed 
with Agilent MassHunter Quantitative. Before any statisti-
cal calculation, sample concentrations were normalized by 
IS abundance in order to minimize the response variability 
introduced by the instrument. Moreover, data were filtered 
by coefficient of signal variation (CV) in QCs, considering 
values lower than 30% as acceptable.
LC–MS data treatment The resulting data file obtained 
by the LC–MS was cleaned of background noise and unre-
lated ions by the Molecular Feature Extraction (MFE) tool 
in MassHunter Profinder software. The MFE then creates 
a list of possible components that represent the full TOF 
mass spectral data features, which are the sum of co-elut-
ing ions that are related by charge-state envelope, isotopic 
distribution and/or the presence of different adducts and 
dimmers. Several parameters of the algorithm were set for 
data extraction, applying 300 counts as limits for the back-
ground noise. Moreover, the algorithm was applied to find 
co-eluting adducts for the same possible compound, select-
ing +H, +Na, +NH4 and neutral water loss as possible 
adducts for positive ionization. Then, MFE aligns features 
across all sample files using mass and retention time (RT) to 
build a unison spectrum for each compound group, enabling 
the next step of the analysis, the re-extraction of the batch 
files—also known as Batch Recursive Feature Extraction 
(RFE). RFE performs MFE again and then uses the mass 
and RT of the results to improve the quality of the target 
list referred to as Find by Ion (FbI) and the quality of the 
final compound group list. Thereafter, the metabolomic data 
obtained were filtered by CV in QCs, keeping metabolites 
with CVs in QCs lower than 30%.
Statistical analysis
Differences among the groups were investigated using uni-
variate data analysis (UVDA) and multivariate data analy-
sis (MVDA). For UVDA, differences between the three 
post-mortem stages were evaluated for each individual 
metabolite using MATLAB (R2015a, MathWorks) by one-
way ANOVA (p ≤ 0.05) validated by Levene’s test, testing 
the homogeneity of variance and trusting only p values with 
p Levene higher than 0.05. Where statistical differences 
appeared by using ANOVA for any of the comparisons, dif-
ferences among the means were compared using Tukey’s 
test in order to find which comparisons were statistically 
significant and the trend of the metabolite concentration. 
For multiple comparison correction, the Benjamini–Hoch-
berg method was applied to all p values to control the false-
positive rate at level α = 0.05. Metabolites whose levels 
had a tendency to change according to the PT interval were 
maintained even if they did not pass this restrictive correc-
tion for enhanced information. The F statistic was obtained 
to reflect the PT effects. Finally, a post hoc pairwise com-
parison with two-sample t test was performed to conclude 
whether the metabolite is significant or not in a comparison 
(Krzywinski and Altman 2014). All these parameters are 
represented in the graphics in Supplementary Fig. S1 of the 
Supplementary Information. For MVDA, SIMCA-P + 12.0 
(Umetrics, Umea, Sweden) was used. As a first exploratory 
step, unsupervised principal component analysis (PCA) 
was generated for a preliminary evaluation of natural clus-
tering of the samples and examination of grouping of QC 
samples that is indicative of stability in the analysis per-
formance. In addition, supervised models such as partial 
least square discriminant analysis (PLS-DA) and orthogo-
nal PLS discriminant analysis (OPLS-DA) were also built. 
The quality of the models was assessed by the explained 
variance  (R2) and the predicted variance  (Q2), supplied by 
the software. Finally, statistically significant variables were 
selected according to the variable importance in projection 
(VIP) and jackknifing confidence interval from the OPLS-
DA models. The metabolites that were assumed to be the 
most meaningful ones for the comparison were those with 
a VIP score ≥ 1 and a jackknife not including 0. Finally, 
fold change was calculated for each metabolite, in order 
to estimate the variation in the abundance of the metabo-
lites within each comparison. In the present study, the per-
centage of change showed a general positive trend, which 
means that the level of metabolites increased over time. 
Metabolites with a percentage of change greater than 30% 
were considered statistically significant.
Compound identification
Putative identification of statistically significant features 
for the LC–MS analysis was achieved by searching the 
list of m/z against the databases available online, such as 
METLIN (http://metlin.scripps.edu), lipidsMAPS (http://
lipidMAPS.org) and KEGG (http://www.genome.jp/kegg/), 
all of which have been integrated into an in-house devel-
oped search engine, CEU MassMediator (http://ceumass.
eps.uspceu.es/mediator). HMDB (http://hmdb.ca) was also 
accessed for supplementary information. Features that were 
putatively assigned to lipids from the databases were based 
on: (1) mass accuracy (maximum error mass 20 ppm); (2) 
isotopic pattern distribution; (3) possibility of cation and 
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Histological studies were performed in mouse brain har-
vested at different post-mortem times (PT, 0  h, 0  min), 
30  min, 1  h, 2  h, 3  h and 5  h and subsequently fixed by 
immersion in 4% paraformaldehyde in PB versus mouse 
brain transcardially perfused with the same fixative. We 
have evaluated the effects that the post-mortem delay in 
the fixation procedure might have on the distribution and 
intensity of the staining after different histological proce-
dures. Since small changes visualized using histological, 
histochemical and immunohistochemical techniques are 
typically found from experiment to experiment, even using 
sections from the same brains, subtle changes are difficult 
to interpret. Thus, we were only looking for large, obvi-
ous changes. Therefore, we have qualitatively analyzed the 
staining patterns in the different subdivisions of the dorsal 
hippocampus (dentate gyrus and CA1, CA2 and CA3) from 
Bregma −1.46 to −2.30 (Paxinos and Franklin 2001).
Neuronal markers
General markers We first used an antibody for NeuN, 
which specifically recognizes a soluble, nuclear, neural 
vertebrate DNA-binding protein that is present in the vast 
majority of mature neurons in both the central and periph-
eral nervous systems of several vertebrate species, including 
humans (Mullen et al. 1992; Wolf et al. 1996; Sarnat et al. 
1998). Immunostaining for NeuN in the immersion-fixed 
brain material labeled virtually all neurons, which allowed 
the cytoarchitectonic features of the different regions and 
the limits between them to be distinguished. Although no 
quantitative evaluation of the neuronal number or intensity 
of immunostaining was performed, we found differences in 
the pattern of immunostaining for NeuN in the hippocampus 
between brains fixed by immersion (Fig. 1a–c), and between 
these brains and perfused brains (Supplementary Fig. S2). 
As shown in Fig.  1, there was a clear decrease in NeuN 
immunostaining in the stratum pyramidale of CA3 close to 
the boundary with CA2 in animals from 30 min PT (Fig. 1d) 
onward that was more pronounced at 5 h PT (Fig. 1e). How-
ever, in the brain of mice fixed by immersion immediately 
after death (PT 0 h, 0 min), NeuN immunostaining was sim-
ilar to that found in perfused animals (see Supplementary 
Fig. S2, A, B).
Markers for subpopulations of neurons We also examined 
whether the fixation procedure and PT affected the stain-
ing of various neuronal subpopulations using immunocyto-
chemistry with SMI-32, parvalbumin (PV) and calbindin-
D28K (CB) antibodies, and the histochemical staining for 
NADPH-d.
SMI-32 is a marker of neuronal subtypes including 
pyramidal cells and interneurons in the neocortex and hip-
pocampus (Mikuni et al. 1998). In line with these studies, 
in our material from perfused animals, SMI-32-ir neuronal 
somata were mainly found in the subgranular zone and 
polymorphic layer of the dentate gyrus (Supplementary 
Fig. S3) and in the strata pyramidale and oriens of the CA 
fields. In the brain of animals fixed by immersion after dif-
ferent post-mortem periods, a similar pattern of SMI-32 
immunostaining of cell somata and processes to that of per-
fused brains was found (Supplementary Fig. S3).
The distribution patterns and apparent density of the dif-
ferent subpopulations of neurons positive for PV, CB and 
NADPH-d found in the hippocampus were in agreement 
with previous studies (Celio 1990; Celio and Heizmann 
1981; Tamamaki et  al. 2003; Maskey et  al. 2012; DeFel-
ipe 1997). However, as shown in Supplementary Figs. S4, 
S5 and S6, there were marked changes including increases 
and decreases in the labeling of elements (cell bodies, neu-
ronal processes or puncta) depending on the hippocampal 
region and layer examined in immersion-fixed tissue from 
30 min to 5 h PT as compared to tissue from perfused ani-
mals. These changes occurred after 30 min in the case of 
CB-immunostaining and NADPH-d histochemical staining 
and after 2 h in the case of PV. For example, among other 
changes, there was a clear reduction in the labeling of PV-
immunostaining processes and an increase in the NADPH-
d staining in the stratum pyramidale of CA1 and CA3, 
after 2 h in the case of PV and after 30 min in the case of 
NADPH-d histochemical staining.
Labeling of  glutamatergic axon terminals In perfused 
brain material, immunostaining for vesicular glutamate 
transporters vGlut1 and vGlut2—the two major isoforms in 
the brain (Nakamura et al. 2005)—labeled numerous punc-
tate elements in the neuropil of neocortex and hippocampus 
that, according to previous studies, are known to correspond 
to excitatory terminals that form asymmetric synapses 
(Fagg and Foster 1983; Fonnum 1984; Danbolt 2001; Ni 
et al. 1995; Hisano et al. 2000; Fujiyama et al. 2001; Her-
zog et al. 2001; Kaneko and Fujiyama 2002; Varoqui et al. 
2002; Kaneko et al. 2002; Miyazaki et al. 2003; Hioki et al. 
2003; Fremeau et al. 2001, 2004; Takamori 2006). Accord-
ing to these studies, vGlut1 and vGlut2 were found partially 
segregated showing a roughly complementary distribu-
tion. vGlut1-ir punctate elements were widely distributed 
throughout the stratum lacunosum moleculare, radiatum 
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and oriens of the hippocampus, as well as the molecular 
layer of the DG and the polymorphic layer of hilus (Fig. 2). 
By contrast, vGlut2-ir terminals were chiefly concentrated 
in stratum pyramidale (Fig. 2) and the molecular layer of the 
dentate gyrus. Although no quantification of either the ter-
minals or intensity of immunostaining was performed, these 
patterns of vGlut1 and vGlut2 immunostaining were similar 
between immersion-fixed tissue with different PT and tissue 
from perfused animals (Fig. 2).
Labeling of  GABAergic axon terminals Immunostaining 
for the vesicular GABA transporter (vGAT), known to cor-
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respond to GABAergic inhibitory axon terminals (Chaudhry 
et al. 1998; Minelli et al. 2003), labeled numerous terminal-
like puncta in the neuropil in the cerebral cortex. In the hip-
pocampus, vGAT-ir puncta were particularly evident in the 
dentate gyrus at the border between the granule cell layer 
and the molecular layer as well as in the stratum pyramidale 
of the CA hippocampal regions. These patterns of vGAT 
immunostaining were again similar between immersion-
fixed tissue and tissue from perfused animals (Fig. 2). Fur-
thermore, we used immunohistochemistry for the 65-kDa 
isoform of the GABA-synthesizing enzyme glutamic acid 
decarboxylase (GAD-65), which is particularly prominent 
in axon terminals, whereas no or very few labeled cell bod-
ies are immunostained (Esclapez et al. 1994). This pattern 
of GAD-65 immunostaining was observed in tissue from 
perfused animals (Fig. 3a, c), whereas in immersion-fixed 
tissue from 30 min to 5 h, numerous labeled cell bodies were 
observed in the hippocampus (Fig. 3b, d) as well as in many 
other brain regions (not shown). No apparent changes were 
seen at 0′ h, 0′ min.
Labeling of extracellular matrix We have also examined 
whether the fixation procedure and the PT delay affected 
components of the extracellular matrix using labeling with 
Wisteria floribunda lectin (WFL) that recognizes N-acetyl-
galactosamine residues in the extracellular matrix in peri-
neuronal nets that wrap PV-positive GABAergic interneu-
rons (Foster et al. 2014; Kosaka and Heizmann 1989) both 
in neocortex and in hippocampus. We found that WFA labe-
ling of perineuronal net-like structures is well preserved in 
immersion-fixed tissue with the different PT and similar to 
that in brains from perfused animals (Supplementary Figs. 
S3 and S6). This suggests that the integrity of the extracel-
lular matrix surrounding PV-positive GABAergic neurons is 
not significantly altered during the first 5 h PT.
Glial markers
Finally, we examined whether the fixation procedure and 
the PT delay affected astrocytes and microglial cells in sec-
tions, respectively, immunostained for glial fibrilar acid 
protein (GFAP) and the EF-hand protein Iba1, which is 
specifically expressed in microglia (Imai et  al. 1996). No 
general differences in the labeling of these two popula-
tions of glial cells were found in the most neocortical and 
hippocampal regions between the perfusion-fixed tissue 
and tissue fixed by immersion after different PT (Fig.  4). 
However, morphological differences in Iba1-ir microglial 
cells were found between perfusion-fixed tissue and tissue 
that was immersion-fixed from 2 to 5 h in those regions in 
which a decrease in the neuronal expression of NeuN was 
noted, including the retrosplenial cortex and the CA3 hip-
pocampal field (Fig. 4c, d). Here, in line with the morpho-
logical descriptions of microglial cells in different patho-
logical conditions (Soltys et al. 2001; Kabadi et al. 2012) 
(Zhan et al. 2008), in the present study Iba1-ir cells showed 
a proinflammatory phenotype ranging from hypertrophic 
microglia (with larger cell bodies and thick, retracted pro-
cesses) to bushy microglia (with numerous but short and 
poorly ramified processes of different diameters forming 
thick bundles around their enlarged cell bodies) (Fig. 4d).
In summary, the marked differences that we observed 
in the tissue fixed by immersion after different PTs when 
compared with the perfusion-fixed tissue were: (1) an obvi-
ous focal decrease in the immunostaining for NeuN in the 
stratum pyramidale of CA3, particularly close to the bound-
ary with CA2 after 30 min; (2) marked changes in PV- and 
CB-immunostaining, and NADPH-d histochemical stain-
ing including increases and decreases in the labeling of 
elements depending on the hippocampal region and layer 
examined, after 30 min in the case of CB-immunostaining 
and NADPH-d histochemical staining and after 2 h in the 
case of PV; (3) an increase in the number of cell bodies 
immunostained for GAD-65 throughout the hippocam-
pus after 30 min; and (4) morphological changes in Iba1-
ir microglial cells (proinflammatory phenotype) after 2  h 
in those regions in which a focal decrease in the neuronal 
expression of NeuN was observed. All these differences 
were more apparent in the 5-h PT tissue.
Metabolomics studies
Regarding metabolomics studies, an initial PCA plot of 
both LC–MS and GC–MS from metabolomic data was gen-
erated to check the clustering of the QC samples and deter-
mine the robustness of the methodology. The QC samples 
Fig. 1  Post-mortem time-related alterations of NeuN immunostain-
ing in mouse cerebral cortex. a, b Low-magnification photomicro-
graphs showing NeuN immunostaining of sections from the neo-
cortex and hippocampus of the brain of mice fixed by immersion 
immediately after death (PT 0  h, 0  min) (a) or by immersion after 
5 h PT (b). Note that in b there are zones with a reduction of NeuN 
immunostaining in the retrosplenial cortex (asterisk) and the CA3 
hippocampal region (arrow). However, in the retrosplenial cortex, 
these changes were already observed at 0 h (0 min), whereas in CA3, 
it was observed from 30 min to 5 h. c, d, e High-magnification pho-
tomicrographs showing the reduction in the number of NeuN-ir neu-
rons in the stratum pyramidale of CA3 in animals with 30 min PT (d) 
and, more markedly, with 5 h PT (e) versus immersion-fixed brain tis-
sue that was extracted immediately after death (PT 0 h, 0 min) (c) or 
perfusion-fixed tissue (see Supplementary Fig. 1S2 A, B). Rectangles 
in a and b indicate the areas of magnification in c and e, respectively. 
f–i Confocal images taken from the pyramidal cell layer of CA3 (f, g) 
and layers II and III of retrosplenial cortex (h, i) of sections immu-
nostained for NeuN and counterstained with DAPI in perfusion-fixed 
tissue (f, h) and immersion-fixed tissue 5  h PT (g, i). Arrow heads 
point to DAPI staining of the nucleus of neurons devoid of NeuN 
immunostaining. Scale bar (in i): 330 µm in (a), B; 80 µm in (c–e); 
15 µm in (f–i)
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were tightly clustered for both analyses, indicating the sta-
bility and reproducibility of the system.
Seven hundred and fifty-six and 58 entities were 
obtained in LC–MS and GC–MS, respectively. Data sets 
after filtering consisted of 704 entities in LC–MS and 45 
identified compounds in GC–MS. PCA modeling showed 
a tendency of sample grouping according to time stage. 
Additionally, supervised PLS-DA models were built for the 
three groups and demonstrated a clear separation between 
them, suggesting that metabolite levels change with time 
after death. PCA plots and PLS-DA plots for GC–MS 
and LC–MS are illustrated in supplementary Fig. S7. For 
OPLS-DA models, differences between post-mortem stages 
were evaluated by pairs and validated by cross-validation, 
leaving one sample out per group. Results are represented 
in Fig. S8, including the  R2 and  Q2 for each comparison 
model.
Parallel to multivariate analysis, univariate statistical 
analysis was performed in order to determine the statistical 
significance of each metabolite separately. After univari-
ate and multivariate data analysis, 22 and 14 compounds 
were shown to be statistically significant for LC–MS and 
GC–MS, respectively. Finally, identified metabolites are 
listed in Table 1 arranged in different biochemical catego-
ries, reflecting features such as retention time, the monoi-
sotopic mass, molecular formula, error mass, among oth-
ers. In the table, a general positive trend can be observed, 
which means that the level of metabolites increased over 
time. Compounds identified by LC–MS presented a bigger 
increase between 30  min and 2  h PT since the increment 
showed at 5 h PT was nearly as high as in the first period 
of time.
Discussion
Autopsy tissue is rarely obtained within 2  h of post-mor-
tem. In the present study, we considered 30  min to be a 
feasible optimal lower limit to obtain post-mortem human 
brain tissue, taking into account the time required to fol-
low necessary procedures between death and dissection. 
To evaluate the effects of these post-mortem periods, we 
compared mouse brain tissue fixed after different PT peri-
ods of up to 5  h. According to the neuroanatomical and 
metabolomic results obtained in this study, significant 
metabolomic changes already began at 2  h PT, whereas 
neuroanatomical observations revealed that although the 
general patterns of labeling for the markers used here 
were preserved, there were selective changes produced 
in immersion-fixed tissue depending on the post-mortem 
time. These changes occurred mostly at 5  h PT. Since 
some neurochemical characteristics of brain tissue that was 
extracted immediately after death and fixed by immersion 
were different compared with the perfused brains, these 
results indicate that the method of fixation per se (i.e., per-
fused versus non-perfused brains) may influence the results 
of the immunostaining.
The levels of many relevant metabolites evaluated by 
metabolic procedures increased until 2 h PT and then their 
levels either remained stable up to 5 h PT (as was the case 
for pyroglutamic acid, anandamide and urea) or decreased 
(as was the case for glycerophosphocholine). Other metab-
olites—such as GABA, creatinine, N-acetyl-aspartic acid, 
putrescine and cadaverine—reached higher levels at 5  h 
PT. Cholesterol and cholesterol esters and other compounds 
like arachidonoylglycerol were stable. Therefore, the pre-
sent results indicate that caution is required when perform-
ing neuroanatomical and metabolomics post-mortem quan-
titative studies, especially in anatomical areas with a high 
sensitivity for oxidative damage and conditions of anoxia. 
Although assessing whether there were any correlations 
between anatomical and metabolomics results was not the 
aim of this study, what follows is a discussion of the pos-
sible significance of the changes found in our study as a 
whole (referring to the present study unless otherwise spec-
ified). The increased concentrations of some amino acids 
observed post-mortem by GC–MS analysis may occur due 
to catabolic reactions of glutathione (GSH). The amino 
acids coming from the tripeptide GSH are glycine, cysteine 
and pyroglutamic acid (Dringen 2000). There was a clear 
trend for these amino acids to increase in concentration, 
with the exception of cysteine, which is made unstable by 
the oxidation of the thiol group and is thus not detected. 
One of the main physiological roles of GSH is the cellu-
lar defense against reactive oxygen species (ROS). These 
radicals are generated at high rates within the brain, which, 
compared with other organs, seems to be especially endan-
gered by the generation and detoxification of ROS (Dringen 
2000; Dringen et al. 2000). The hippocampus is especially 
sensitive to oxidative stress; it has a high oxygen consump-
tion and is rich in lipids with unsaturated fatty acids, the 
Fig. 2  Distribution of glutamatergic axon terminals and GABAergic 
axon terminal immunoreactivity in the CA1 hippocampal region. a, 
b Low-magnification photomicrographs showing the similar distribu-
tion and intensity of immunostaining of vGLUT1 in the hippocampus 
of perfusion-fixed animals (a) and brains fixed by immersion after 
5 h PT (b). c–t Pairs of confocal images from the CA1 region taken 
from sections immunostained for vGLUT1 (C,D,I,J,O,P), v-GLUT2 
(E,F,F,L,Q,R), vGAT (G,H,M,N,S,T) and counterstained with DAPI 
from perfusion-fixed brains (c–h) or brains fixed by immersion after 
30 min (i–n) or 5 h (o–t) PT. Rectangles in a and b indicate the areas 
of magnification in c and o, respectively. Note that vGlut1 and vGlut2 
terminals distribute in a roughly complementary way in CA1. Also 
note the apparent absence of changes in the distribution of vGlut1, 
vGlut2 and vGAT between the brains fixed with different procedures 
and PTs. or, stratum oriens; pyr, stratum pyramidale; rad, stratum 
radiatum. Scale bar (in t): 400 µm in (a, b); 17 µm in (c–t)
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targets of lipid peroxidation (Dringen et al. 2000). Further-
more, the hippocampus has a relatively low content of anti-
oxidants (Evans 1993). Therefore, GSH antioxidant activ-
ity is an essential task for brain function (Dringen 2000). 
GSH is predominantly metabolized through the γ-glutamyl 
cycle (Fig.  5a), which acts by regulating the transit of 
amino acids through the blood–brain barrier, safeguarding 
brain homeostasis (Hawkins et  al. 2006). Resynthesizing 
one mole of GSH requires the hydrolysis of three moles 
of ATP (Harish et al. 2011). As a consequence, the lack of 
ATP related to the post-mortem hypoxia state can compro-
mise the glutathione system. Various papers state that brain 
glutathione content drops rapidly after death, reflecting the 
fact that its metabolism is influenced by post-mortem inter-
val (Donaldson and Lamont 2015; Perry et al. 1981; Harish 
et al. 2011; Epstein et al. 2013). According to the explana-
tion above, increased glycine and pyroglutamic acid levels 
in the hippocampus tissues are consistent with GSH hydrol-
ysis. These findings can affect the interpretation of previous 
studies about altered glutathione metabolism in age-related 
neurodegenerative diseases (Pearce et  al. 1997) (Aoyama 
and Nakaki 2013).
In our tissue, we have not found apparent differences in 
the general distribution of different populations of neurons 
identified by PV-, CB-immunostaining or NADPH-d 
histochemical staining, between the perfusion-fixed tis-
sue and tissue fixed by immersion after up to 5  h of PT 
delay. However, there were marked changes in PV- and 
CB-immunostaining, and NADPH-d histochemical stain-
ing in immersion-fixed tissue, after 30 min in the case of 
CB-immunostaining and NADPH-d histochemical staining 
and after 2 h in the case of PV, as compared to tissue from 
perfused animals. These changes were particularly evident 
at 5 h PT and included increases and decreases in the stain-
ing of labeled cell bodies, neuronal processes or puncta 
depending on the hippocampal region and cortical layer 
examined.
In a previous study carried out in rhesus macaque mon-
keys with longer PT periods (up to 48 h), it was found that 
PV-ir cells presented a low definition of immunostaining of 
the fine dendritic processes (Lavenex et al. 2009). In addi-
tion, the authors reported that SMI-32 immunoreactivity 
was also greatly reduced in somas and dendrites of neurons 
located in several zones of hippocampus (Lavenex et  al. 
2009), whereas we did not find any significant change in 
our immersion-fixed material up to 5 h PT.
The PT delay also affected NeuN immunostaining in 
the CA3 hippocampal region; it was particularly reduced 
Fig. 3  Post-mortem time-
related alterations of GAD-
65-immunostaining in mouse 
hippocampus. Low (a, b)- and 
higher (c, d)-magnification 
photomicrographs (rectangles in 
a and b, respectively) show-
ing the distribution patterns of 
GAD-65-immunoreactivity of 
sections through the hippocam-
pus of mice brains fixed by 
perfusion (a, c) or by immersion 
after 5 h PT (b, d). Note that in 
perfusion-fixed tissue (c) GAD-
65 immunoreactivity is present 
mainly in punctate structures 
(presumptive axon terminals) 
distributed in the neuropil or 
surrounding cell bodies of 
unlabeled neurons. Occasion-
ally, some cell bodies are also 
immunostained (arrows). In 
post-mortem brain tissue, the 
pattern of immunostaining is 
similar to that found in perfused 
brain tissue with the exception 
that a larger number of GAD-
65-ir neurons are stained (d) 
(arrows). or, stratum oriens; pyr, 
stratum pyramidale; rad, stratum 
radiatum. Scale bar: 280 µm in 
(a, b); 30 µm in (c, d)
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after 5 h of PT. In this region, DAPI staining revealed that 
the loss of NeuN immunostaining occurred in the absence 
of apparent cell death. This is in agreement with previous 
reports describing a depletion of NeuN immunoreactivity 
in hypoxic conditions in sudden infant deaths (Lavezzi 
et  al. 2013) and in mouse brains after cerebral ischemia 
(Unal-Cevik et al. 2004). There seems to be a regional vul-
nerability to pathological conditions based on the high rate 
Fig. 4  Post-mortem time-related changes in microglial and astro-
glial cells in the hippocampus. a, b Low-magnification photomicro-
graphs showing Iba-1 (microglial cells; a) and GFAP immunoreac-
tivity (astrocytes; b) in immersion-fixed tissue 5 h PT counterstained 
with methyl green. c, d High-magnification photomicrographs show-
ing that Iba-1-ir microglial cells have larger cell bodies (arrows) and 
thick, retracted processes in immersion-fixed tissue 5  h PT (d) as 
compared to perfusion-fixed tissue (c). e–h Low-magnification pho-
tomicrographs of CA1 (e, g) and the dentate gyrus (f, h) showing 
the absence of apparent differences in the patterns of GFAP immu-
nostaining in the brain of animals fixed by immersion after 5 h PT (g, 
h) compared to animals fixed by perfusion (e, f). DG, dentate gyrus; 
gran, granular layer; lac, stratum lacunosum moleculare; mol, molec-
ular layer; or, stratum oriens; pol, polymorphic layer; pyr, stratum 
pyramidale; rad, stratum radiatum. Scale bar (in h): 300 µm in (a, b); 
16 µm in (c, d); 40 µm in (e–h)
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of oxidative activity and relatively low antioxidant capac-
ity (Igarashi et al. 2001). The CA1 and CA3 hippocampal 
fields and dentate gyrus are especially sensitive to oxidative 
damage (Chang et al. 2012; Uysal et al. 2012). For exam-
ple, peripheral oxidative stress has been strongly associ-
ated with diminished hippocampal volume—a finding that 
Table 1  Metabolites that showed statistical significance any of the post-mortem comparisons at different times in hippocampus
† Alternative identification. Besides all of the metabolic changes observed in this study, it is important to take into account all the compounds 
found in the analysis which showed no significant alterations over time. All these metabolites are summarized in Table 2, next to a summary of 
all the metabolites found to be statistically significant
a CV, coefficient of variation of the metabolites in the QC samples
b p value, corrected p value by Benjamini–Hochberg test correction
c p Levene, p Levene was considered as significant at values higher than 0.05 in order to test homogeneity of variances, NS nonsignificant
d Tukey’s test results colored by significance of the metabolite in the specific comparison (green means the metabolite is significant and is up-
regulated, red means the metabolite is significant and is down-regulated, and gray means the metabolite is not significant)
e FC, fold change in the specified comparison; the sign indicates the direction of change
f VIP, VIP values higher than 1 were considered as significant
g Jackknife confidence interval
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has been most reliably demonstrated in the CA3 and DG 
(Lindqvist et al. 2014). In a PT study on AD, it was sug-
gested that an oxidative stress pathway starts in the CA3 
subfield and then progresses to other hippocampal regions 
and the neocortex (Cruz-Sanchez et al. 2010).
In regions with an obvious decrease in NeuN immu-
nostaining, we found that microglial cells showed a proin-
flammatory phenotype after different PT and more mark-
edly at 5  h PT. In conditions of lack of ATP related to 
post-mortem hypoxia state, it is possible that the microglial 
cells are activated and this status was more evident at 5 h 
PT. We found an increase in GABA and biological com-
pounds from the metabolism of arginine such as urea, poly-
amines, creatine and glutamate at 5 h PT. These metabolites 
can play an important role in the innate immune response, 
through the activation or anti-inflammatory response of 
microglial cells (Pocock and Kettenmann 2007; Colton 
2009; Ahn et al. 2011; Fontainhas et al. 2011). Microglial 
cells arginase I, an inducible cytoplasmic form, and argin-
ase II, a constitutively mitochondrial form (Yu et al. 2003; 
Colton et al. 2006), and the microglial expression of Arg1 
and iNOS can vary with M1 and M2 microglial phenotypes. 
Arg1 and iNOS can be up-regulated during the progres-
sion of amyotrophic lateral sclerosis, and in motor neurons, 
Arg1 may confer protection from disease processes (Lewis 
et al. 2014). The neuroprotective M2 state has been related 
to an anti-inflammatory alternative activation phenotype, 
which participates in repair and resolution to tissue homeo-
stasis in pathological conditions (Colton 2009).
It was noted that the compounds synthesized from 
amino acids increased considerably over time, while only 
small changes in the levels of precursor of amino acids 
were observed. 3-methyl-2-oxobutanoic acid comes from 
valine, leucine and isoleucine pathways. Its percentage 
change was 146% in the comparison 5 h versus 30 min, but 
no evidence of its precursors was found, probably because 
they degraded rapidly.
Creatinine is a compound that is worthy of attention 
since its percentage of change was 239%. Creatinine is 
formed by spontaneous and unidirectional non-enzymatic 
conversion from creatine and, above all, from creatine 
phosphate, which serves as energy storage for the body. By 
transporting phosphates between sites of ATP production 
and ATP consumption, the creatine/phosphoryl-creatine/
Table 2  Metabolite 
classification according to their 
behavior within time
Changes No changes





Amino acids, peptides and analogues  Leucine
 GABA  Serine
 4-guanidinobutyric acid  Threonine
 Glycine Cholesterol and cholesterol esters
 N-acetyl-aspartic acid Fatty acyls
 Pyroglutamic acid  Arachidonic acid
Azolines  Myristic acid
 Creatinine  Oleic acid
Carbohydrates and carbohydrate conjugates  Palmitic acid
 Ribose  Stearic acid
Dicarboxylic acids and derivatives Organic acids
 Succinic acid  3-hydroxybutyric acid
Fatty acyls  Fumaric acid
 3-methyl-2-oxobutanoic acid  Glycolic acid
 Acetylcarnitine  Malic acid
 Anandamide  Phosphoric acid
Glycerolipids Phospholipids and lysophospholipids
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creatinine system acts as an intracellular energy shuttle 
and helps to maintain the energy balance in all tissues with 
high-energy demands, like brain (Donaldson and Lamont 
2015). The level of free creatine in the body is low because 
it is rapidly converted to phosphoryl-creatine by enzyme 
creatine kinase, as well as in the second step of the pro-
cess leading to the final product creatinine (Gallant et  al. 
2006). To obtain creatine phosphate, the hydrolysis of two 
ATP molecules into AMP is required. As a consequence, 
when the levels of ATP drop, creatine phosphate rapidly 
degrades to creatinine. Since no system is activated to 
remove creatinine after death, this substance turns out to be 
a clear marker that there is no more anabolic activity, and 
there is catabolism alone without any form of excretion. 
For this reason, creatinine provides evidence of the time 
elapsed after death and it is used as an index in forensic 
analysis. Since creatine/creatinine metabolism has recently 
been linked to neurodegenerative diseases (Wyss and Kad-
durah-Daouk 2000), PT should be considered in experi-
mental designs.
In addition, the considerable increase of creatinine 
highlighted in this study could be interpreted as being 
Fig. 5  a γ-glutamyl cycle for transporting amino acids coupled to the 
degradation of glutathione. AA is the amino acid being transported 
inside the cell by the ɣ-glutamyl transpeptidase, ɣ-GTP. b Reactions 
involved in creatine/creatinine metabolism and urea cycle coupled 
to catabolism of L-arginine and L-ornithine. The enzymes involved 
in the different steps are: AII arginase II, GATM L-arginine:glycine 
amidinotransferase, ODC ornithine decarboxylase, OAT ornithine, 
DAO diamine oxidase, MAO monoamino oxidase, GAD glutamic 
acid decarboxylase, pyrroline-5-carboxylate (PC5) dehydrogenase. c 
Activation of anandamide synthesis by calcium release. The enzyme 
involved is a specific phospholipase D (NAPE-PLD)
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a consequence of the increased number of metabolites 
involved in the urea cycle, from which creatine derives—
in particular, a clear increase in glycine as previously 
explained. The connection between creatinine and urea 
pathways is shown in Fig. 5b. To date, little is known about 
post-mortem changes in the level of urea, but such accumu-
lation of urea might be due to continued ammonia forma-
tion after death, as a consequence of protein and amino acid 
breakdown by either enzyme or bacterial activity (Jenkins 
1953). Since brain is a very well-isolated system, shortly 
after death, the enzymatic activity prevails over bacterial 
activity and putrefaction is not accentuated.
The multiple metabolic fates of arginine make it one of 
the most versatile amino acids. Indeed, arginine is metabo-
lized through a complex and highly regulated set of path-
ways that leads to the formation of many biologically 
important compounds: urea, polyamines, agmatine, cre-
atine and thus creatinine, and glutamate, which is a precur-
sor for the synthesis of GABA (gamma-aminobutyric acid) 
(Morris 2007). The chemical derivatization of arginine is 
difficult due to the low reactivity of the guanidinium group. 
For this reason, it is rarely identified in GC analysis, but 
most of its metabolites were found in the present investiga-
tion. Researchers have recently become aware that protein 
turnover can release various arginine derivatives (Morris 
2006). This consideration, together with the increase of 
arginine levels due to post-mortem protein breakdown, may 
account for the increasing rate of production of urea, poly-
amines, creatine and glutamate, providing explanation for 
our results. The pathways interconnected by arginine are 
shown in Fig. 5b (Caron et al. 1987).
A further point to note is that putrescine and cadaverine 
belong to the family of biogenic polyamines, which are pre-
sent in relatively high levels in the brain, where they play 
an essential role (Burkard et al. 1963). Measuring polyam-
ines in post-mortem brain tissue is worthwhile consider-
ing recent evidence implicating polyamines in neurologi-
cal disorders (Chen et  al. 2009). Previous studies suggest 
that polyamine levels are stable in rodent autopsied brain 
up to 24 h PT and no correlation between polyamine lev-
els and PT interval was observed (Morrison et  al. 1995). 
By contrast, we found a pronounced increase in putrescine 
and cadaverine, with a high percentage of change (130 and 
105%, respectively) over time. The synthesis of putres-
cine involves an initial input from ornithine decarboxylase 
(ODC), and its substrate, ornithine, is generated from argi-
nine (Morris 2007). As a result, putrescine can be consid-
ered to be one of the metabolites whose high concentration 
can be related to the increase in arginine level resulting 
from the protein breakdown that takes hold after death. 
Moreover, according to published evidence (Seiler 2000), 
ischemic and hypoxic conditions associated with death 
cause an increased activity of ODC, accompanied by an 
increase of putrescine concentration in brain. Interestingly, 
it is not only the activity of ODC that increases; arginine 
decarboxylase activity increases too. Regarding cadaverine, 
there is an endogenous source of this diamine in the mouse 
and it is actually synthesized in mouse brain (Stepitak and 
Dolezalo 1974). In addition, both putrescine and cadaver-
ine are substrates of various amine oxidases (Schmidt-Gle-
newinkel et al. 1977). Several studies have been carried out 
to elucidate the diamine oxidase (DAO)-mediated metabo-
lism of polyamines. It was demonstrated that, after death, 
polyamine metabolism operated by DAO gradually slows 
down. This is compatible with the appreciable increase in 
post-mortem polyamines levels in mouse brain (Stepita-
Klauco and Dolezalova 1974). Moreover, it is interesting to 
note that putrescine also contributes to formation of GABA 
by means of diamine oxidase.
Inside GABAergic neurons, GABA is generated from 
glutamic acid in a single enzymatic step catalyzed by 
glutamate decarboxylase (GAD). Rate limiting this step 
occurs via steric hindrance associated with ATP. This could 
explain the increase in GABA post-mortem when ATP lev-
els drop (Karam 2012). It should also be noted that, since 
the conversion from glutamate to GABA is anaerobic, it 
can continue after death. Circumstantial evidence for the 
role of GABA in anoxic conditions comes from studies 
demonstrating that the lack of oxygen induces a consider-
able increase in the GABA content in brain (Nilsson 1993). 
Taking this into account, the positive trend of GABA was 
predictable. Other investigations based on the measure-
ment of post-mortem changes in mouse brain reported that 
GABA is one of the amino acids that rapidly increase in 
mouse brain after death (Perry et al. 1981). This is in line 
with the obvious increase in the labeling of cell bodies with 
immunocytochemistry using anti-GAD-65 antibodies that 
we observed throughout the hippocampus in post-mortem 
brain tissue.
There was a trend to increase one derivative of aspartic 
acid, N-acetylaspartic (NAA), after death (Simmons et al. 
1991). NAA is the second most concentrated molecule in 
the brain after glutamate, and like glutamate, it may func-
tion as a neurotransmitter (Yan et al. 2003). NAA, which is 
synthesized primarily in neurons, is the second most con-
centrated molecule in the brain after glutamate, and like 
glutamate, it may function as a neurotransmitter (Yan et al. 
2003). However, its role in these cells remains unclear. 
One of the main hypotheses is that NAA is involved in cell 
signaling together with NAAG, controlling the interactions 
of brain cells and preserving the nervous system (Baslow 
2000). NAA is also considered to be an important marker 
of neuronal viability in many cerebral pathologies, where a 
decline in its concentration is interpreted as a sign of neu-
ronal or axonal dysfunction or death (Tyson and Sutherland 
1998). Nevertheless, an increment in NAA concentration 
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also induces many alterations such as oxidative stress, 
Canavan disease or genotoxicity and protein interaction 
due to an increase in nitric oxide produced by the elevated 
concentration of NAA (Surendran and Bhatnagar 2011). 
Compared with other organs, the brain has a high con-
tent of lipids, some two-thirds of which are phospholipids 
(Ohkubo and Tanaka 2010). Hippocampal pyramidal neu-
rons represent by far the most abundant type of neuron in 
the hippocampus, and their dendritic arbor is covered by 
dendritic spines. Dendritic spines are the main target of 
excitatory glutamatergic synapses and are considered to be 
critical for cognition, learning and memory. Thus, many 
researchers are interested in the study of possible altera-
tions of dendritic spines in brain diseases (DeFelipe 2015). 
These structures contain a complex mixture of ions, lipids, 
proteins and other signaling molecules which must be con-
tinually restored (Sorra and Harris 2000). In fact, it is well 
known that cholesterol and sphingolipids (SL) are enriched 
in dendritic spines. The extraction of cholesterol or inhibi-
tion of its synthesis leads to the disappearance of dendritic 
spines, which proves that cholesterol is a core component 
of dendritic spines (Dotti et al. 2014). Cholesterol and cho-
lesterol esters were identified by two techniques (GC–MS 
and LC–MS), but differences over time were not statisti-
cally significant after data analysis, indicating that degrada-
tion 5 h PT is negligible. This is in line with the study by 
Williams et al. (1978); they found no appreciable changes 
in the density and morphology of spines in the dendritic 
arbors of pyramidal neurons of the mouse with fixation 
latencies of 5 min to 6 h, but, with latencies of more than 
6 h, they observed a reduction in the density of dendritic 
spines and morphological changes of these structures. SL 
make up approximately 20% of the hippocampus, including 
sphingomyelin, cerebrosides, cerebroside sulfates and gan-
gliosides. SL act as important signaling molecules in neu-
ronal tissue, and they have received wide attention due to 
the relatively high levels of gangliosides found. However, 
recent studies have shown that simple SL, such as ceramide, 
sphingosine-1-phosphate and glucosylceramide (GlcCer), 
also play important roles in neuronal function such as in 
regulation of neuronal growth rates, differentiation and cell 
death (Buccoliero and Futerman 2003). Ceramide, a second 
messenger in neurons, contributes to spine plasticity thanks 
to its capacity to favor membrane fusogenicity promoting 
receptor clustering (Kronke 1999). Although ceramide is 
the best characterized SL, its glucosyl derivative, GlcCer 
also has important functions since it regulates the rate of 
axonal and dendritic growth (Boldin and Futerman 1997; 
Harel and Futerman 1993). However, GlcCer is found 
in low concentrations since it is a metabolic intermediate 
in the biosynthetic pathway leading to formation of other 
GSLs. The proper formation and long-term maintenance of 
neuronal connectivity are crucial for correct functioning of 
the brain. The long-lasting stability of dendrite and spine 
structure in the nervous system is highly dependent on the 
actin cytoskeleton, which is particularly well developed 
in these structures (Koleske 2013). Sphingomyelin, one 
of the most abundant SL in neuronal membranes, has an 
important role in the spine membrane–cytoskeleton cross 
talk since it modulates membrane binding and the activ-
ity of main regulators of the actin cytoskeleton at synapses 
(Dotti et al. 2014). Sphingosine 1-phosphate is a bioactive 
lipid that controls a wide range of the cellular processes 
described above, and it is also involved in cytoskeletal 
organization. Moreover, it plays a pivotal role is the forma-
tion of memory (Kanno et al. 2010). However, no signifi-
cant differences in any of these compounds were observed 
over time.
Phospholipids, such as phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE), are the two major phos-
pholipid classes of brain membranes, and from previous 
experimental studies, reduction of total PC and PE mass 
might be expected during brain degeneration post-mortem. 
Nevertheless, due to the high content of these phospholip-
ids, only extensive breakdown (>10%) of these compounds 
will be visible as significant changes in tissue homogenates 
(Klein 2000). Numerous studies have addressed the ques-
tion of whether the hypothesized activations of phospholi-
pases are visible in post-mortem tissue. The enzyme phos-
pholipase  A2  (PLA2) recognizes the sn-2 fatty acyl bond 
of phospholipids and catalyzes the hydrolysis of the bond, 
releasing free fatty acids and lysophospholipids (Dennis 
1994). Since no Lyso-PC was statistically significant, we 
can assume that phospholipase  A2  (PLA2) does not change 
its activity post-mortem.
As described in the literature, triacylglycerol (TAG) 
is quantitatively a minor component of the whole brain, 
representing <0.2% of total brain lipid, but its levels can 
become increased in pathological conditions. However, low 
levels of TAG in brain do not indicate low metabolic activ-
ity for this neutral lipid fraction: Low concentration of free 
fatty acids (FA) in total brain lipid composition could be 
due to the direct exchange of acyl chains between TAG, not 
releasing free FA in this process; thus, the lack of a statisti-
cally significant outcome for FA could be explained (Cook 
1981; Smith and White 1968). Given that TAG is present 
in low concentrations in brain tissue, it can be assumed 
that all the diacylglycerols (DAG) and monoacylglycer-
ols (MAG) reflected as statistically significant come from 
glycerophospholipids. Brain tissue contains several classes 
of glycerophospholipids, with different rates of turnover 
depending on their structure and localization. Glycerophos-
pholipids are vulnerable to being catabolized by phospho-
lipases  A1,  A2, C and D yielding different second messen-
gers. Phospholipase C (PLC) performs the hydrolysis of 
the phosphodiester bond at the sn-3 position leading to the 
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formation of DAG (Farooqui et al. 2000). Since DAGs are 
products of phospholipase C, a global increase in its activ-
ity can be assumed. The two statistically significant mono-
glycerides obtained, monopalmitin [MG(16:0)] and mon-
ostearin [MG(18:0)], were previously described in brain 
tissue (Rowe 1969).
Glycerophosphocholine (GPCh) is present in rela-
tively high concentration in brain tissue. It was previously 
reported that GPCh concentration decreased progressively 
in the first hour PT in the striatum and cortex of rat brain 
(Jope and Jenden 1979). As can be observed in Table 1, the 
abundance of GPCh decreased until 2 h PT, and after 5 h, 
its abundance was no lower than at 2 h.
The endogenous cannabinoid system has been studied 
in great detail in the hippocampal formation, where there 
is a high density of cannabinoid binding sites (Hajos et al. 
2000). The endocannabinoid (eCB) system is a retrograde 
signaling system composed of lipid mediators, the endo-
cannabinoids and cannabinoid receptors type 1 (CB1) and 
type 2 (CB2). The main expression sites of these receptors 
are different: CB1 is expressed in brain, peripheral nervous 
system, gastrointestinal tract, heart, liver, adipose tissue, 
lungs, adrenal glands, smooth and skeletal muscle, male 
and female reproductive systems, bone and skin; CB2 is 
expressed in a very low concentration in brain, restricted 
to specific neuronal cells, and is present in high levels in 
microglia and astrocytes and abundantly expressed in 
immune system cells (monocytes, macrophages, and B 
and T cells) and peripheral organs (spleen, tonsils, thy-
mus gland, mast cells, keratinocytes and gastrointestinal 
system). Finally, the eCB system also consists of enzymes 
involved in the synthesis and degradation of endocannabi-
noids. The main endocannabinoids of the CB1 receptor are 
2-arachidonoylglycerol (2-AG) and anandamide (AEA) 
(Piyanoya et  al. 2015). The concentration of these com-
pounds in the hippocampus is approximately twice that 
found in the cortex (Maccarrone et  al. 2002). AEA and 
2-AG belong to the lipid families of N-acylethanolamines 
(NAEs) and 2-monoacylglycerols (2-MAGs), respectively. 
The phospholipid precursors of NAEs, N-acylethanolamine 
phospholipids (NAPE), are accumulated in the rat brain 
rapidly post-mortem (Natarajan et  al. 1986), which led to 
the hypothesis that accumulation of these substances may 
be due to neuronal death. This concept is consistent with 
previous findings, based on several animal models (Schmid 
et al. 1995). The synthesis of these compounds is calcium-
regulated, and as described above, after death, the calcium 
contained in cells is released by cellular lysis. When cal-
cium concentrations rise, the main enzymes for generation 
of AEA and 2-AG are stimulated, that is, N-acyltransferase 
and phosphoinositide-specific phospholipase C, respec-
tively. Their activation results in the formation of a vari-
ety of NAPE and DAG species, respectively, and the 
corresponding NAE and 2-MAG species are released by 
the activation of a NAPE-specific phospholipase D and a 
stereoselective DAG lipase (Hansen et al. 2001). All these 
reactions are represented in Fig.  5c. However, only AEA 
levels increased until 2 h PT, and then, its levels were sta-
ble, while 2-AG levels did not change with time. These 
results are in agreement with a previous study by Palkovits 
et al. (2008), in which the concentration of AEA in human 
hippocampal tissue with 2–3 h PT was found to be almost 
double that of 1–1.5  h PT, and no further increase was 
observed at 4–6 h PT (Palkovits et al. 2008).
In conclusion, the present results indicate that PT delays 
of up to 5  h do not affect the general pattern of labeling 
of a number of neuronal systems and glial cells in the hip-
pocampus, and this is also the case for many metabolites. 
However, there are also highly significant changes—not 
only in the levels of a variety of metabolites, but also PT-
dependent changes in the immunostaining or histochemi-
cal staining using certain markers of neurons and microglia 
that are commonly used to analyze the human brain both in 
health and in disease. Thus, knowledge of which metabo-
lites are stable, and which are susceptible to change, as well 
as information regarding the neuroanatomical/neurochemi-
cal characteristics of neurons and glia at any given PT 
delay, is essential in order to make interpretations of studies 
using human brain autopsies.
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